Nucleix
Urine-based test for detecting bladder cancer
Nucleix has raised €49M across 2 funding rounds from 3 investors, most recently a round in Apr 2021. Based in Rehovot, Israel; founded 2008; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€49M
€49,262,817
Funding rounds
2
Investors
3
distinct backers
Active since
2016-05
latest 2021-04
Funding by year
EUR raised per yearNucleix — funding by year — interactive chart.
Data table
| Nucleix — funding by year | |
|---|---|
| 2016 | €2.7M |
| 2021 | €47M |
Signals
High confidenceRaise-next likelihood6
base rate 30% for Other
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood7
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ Old (18y) — past typical exit age
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-04-07 | Other | €47M | RA Capital Management | View deal → |
| 2016-05-01 | Seed | €2.7M | Aurum Ventures,OrbiMed | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Trax€789MIsrael · Software
Global coverage: FundingData